TransCode Therapeutics, Inc.
RNAZAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Apr 16, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 13, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 6, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 24, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 29, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 3, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 24, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 14, 2023 |
| HC Wainwright & Co. | maintain | Buy | Nov 15, 2022 |
| HC Wainwright & Co. | maintain | Buy | Jun 7, 2022 |
Earnings History
Next report: Nov 18, 2026| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-7.17 | — | — | — |
| May 15, 2026 | $-21.28 | — | — | — |
| Apr 15, 2026 | $-18.58 | $-10.08 | — | — |
| Nov 14, 2025 | $-5.49 | $-9.24 | — | — |
| Aug 14, 2025 | $-4.94 | $-8.68 | — | — |
| May 21, 2025 | $-70.28 | $-2.00 | — | — |
| Apr 7, 2025 | $-8.50 | $-3.21 | — | $300.0K |
| Nov 14, 2024 | $-147.91 | $-452.76 | — | $300.0K |
News
Lead program TTX-MC138 is in Phase 2a clinical development for ctDNA-positive colorectal cancer following curative-intent treatment TransCode will evaluate strategic alternatives including licensing arrangements, development partnerships and other strategic transactions BOSTON, Oct. 28, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), a clinical-stage biopharmaceutical company developing RNA-based therapeutics and immuno-oncology treatments for hig…
Poster highlights durable disease control, acceptable tolerability and exploratory evidence of treatment-associated antitumor immune activity in patients with advanced solid tumors BOSTON, Oct. 26, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high-risk and advanced cancers, released its poster 1025P describing the clinical results from its Phase 1a clinical trial of TTX-MC138 …
Poster presentation to highlight the Phase 1a clinical evaluation of TTX-MC138 in patients with advanced solid tumors BOSTON, Oct. 19, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high risk and advanced cancers, today announced that a poster featuring TTX-MC138, the Company's lead therapeutic candidate, has been accepted and will be presented at the European Society for Medica…
[url="]Natera, Inc.[/url] (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and [url="]TransCode Therapeutics, Inc[/url]. (Nasdaq: RNAZ),
AUSTIN, Texas, & BOSTON--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high-risk and advanced cancers, today announced a strategic collaboration in colorectal cancer (CRC). The collaboration will support enrollment for TransCode's Phase 2a trial evaluating TTX-MC138 in patients with CRC. Pati.
Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors In the 14 efficacy-evaluable patients: 71.4% stable disease rate 57.1% of patients had disease control through three months of therapy 36.7% maintained disease control through six months of therapy Three efficacy-evaluable patients remain progression-free at one year Exploratory blood RNA-sequencing showed treatment-associated antitumor immune activation and biological featur…
Allowances of Patent Applications in Australia and Japan support differentiated RNA platform for targeted cancer therapy and immune modulation BOSTON, Sept. 22, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced significant advancements in its global intellectual property portfolio, highlighted by (i) the acceptance of an Australian patent application and…
TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript
Tom Fitzgerald, Chief Financial Officer, Announces his Retirement John Tattory, to become Interim Chief Financial Officer BOSTON, Sept. 10, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the retirement of its Chief Financial Officer, Tom Fitzgerald.
Published study in Cancers highlights therapeutic potential of targeting microRNA-10b in bone metastasis with TransCode's lead therapeutic candidate BOSTON, Aug. 31, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a peer-reviewed article in Cancers titled, "Targeting miR-10b in Breast Cancer Bone Colonization Mode…